Investigational Drug for the treatment of Nonalcoholic Steatohepatitis (NASH)

Trial ID:
Paul J. Pockros, M.D.
This study is evaluating how safe and effective the investigational drug Obeticholic Acid (OCA) may be in delaying or preventing medical conditions or health...

Inclusion Criteria

  • Be 18 years or over
  • Have been diagnosed with NASH with fibrosis by liver biopsy
  • Have a stable body weight for at least 3 months

Exclusion Criteria

  • Have had bariatric surgery
  • Have type 1 diabetes, cirrhosis, known heart failure, or uncontrolled high blood pressure
  • Have unstable diabetes Type 2
  • Be pregnant or planning a pregnancy
  • Be unwilling to use birth control if able to get pregnant

Additional Info

  • Patients will be randomized to receive 10mg of OCA, 25mg of OCA, or a matching placebo once a day for the duration of the study, in conjunction with local standard of care.

Contact Info:

  • Shannon Cyhan